Skip to main content

Nilotinib + BRAF/MEK Inhibitor Therapy

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

  • RegistryNCT04903119
  • PhasePhase 1
  • StatusRecruiting
  • ConditionBRAF V600 Metastatic or Unresectable Melanoma
  • SponsorRina Plattner
How Nilotinib worksNCT049031191 min

What the film says

Read the transcript

This trial is for adults with metastatic or unresectable melanoma that has a BRAF V600 mutation and has come back after BRAF and MEK inhibitor therapy.

The idea: add nilotinib, a daily pill at rising doses, to a fixed regimen of dabrafenib and trametinib, or of encorafenib and binimetinib. The study looks for the highest safe dose of nilotinib in the combination.

This phase 1 study plans 30 patients. At the University of Kentucky, Ruta Arays and Rina Plattner lead it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04903119

    Adults; metastatic/unresectable BRAF V600 melanoma relapsed after BRAF/MEK inhibitors; Nilotinib rising doses with dabrafenib/trametinib or encorafenib/binimetinib; Highest safe dose of nilotinib in the combination; Phase 1; 30 patients (+1 more lines)

The drug

What is being tested.

Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.

After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days.

This is a phase 1 dose-escalation study of nilotinib in combination with a fixed-dose of dabrafenib and trametinib or with encorafenib and binimetinib. The first week, patients will be treated with dabrafenib (150mg, twice daily) and trametinib (2mg, once daily), or encorafenib (450 mg, daily) and binimetinib (45 mg twice daily).

The study

How the trial runs.

This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy.

The goal is to assess the toxicity and tolerability and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of the combination of nilotinib with dabrafenib and trametinib or with encorafenib and binimetinib. Additionally, this study will assess pharmacokinetic parameters of dabrafenib and nilotinib when used in combination.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • 1.1 Patients must have histologically confirmed metastatic or unresectable melanoma.
  • Radiological evaluation should occur within 28 days prior to enrollment initiation.
  • 1.2 Patients must have a BRAF V600 mutation. Any CLIA-certified mutation testing is acceptable to document mutation status.
  • 1.3 Patients must have stable disease on dabrafenib and trametinib or on encorafenib and binimetinib for a duration of greater than or equal to 3 months OR have failed any BRAFi/MEKi regimen to qualify for the trial, including the dabrafenib/trametinib combination and/or the encorafenib/ binimetinib combination.
  • 1.4 Patient may have had prior immunotherapy for metastatic disease or prior cellular therapy (although NOT mandatory). NOTE: Other prior therapies are not allowed, with the exception of radiation.
  • 1.6 ECOG performance status ≤ 1. See Appendix A.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.